Nature Biotechnology’s academic spinouts of 2019 | Nature Biotechnology
Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report.
Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report. Access options Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and…
saved by
related reading
- Requests for Startups | Y Combinatorycombinator.com
- Biotech Startups: Move Slow and Fix Things - Stanford Biotechnology Groupstanfordbiotechgroup.com
- Unblock research bottlenecks with non-profit start-upsnature.com
- How biotechnology could shape the future of product design | Next Naturenextnature.net
- The sprint to solve coronavirus protein structures — and disarm them with drugsnature.com
- List of Biotechnology Companies to Watch – AI Expanded Versionsubstack.com
- The Biotech Delusion: Things No One Wants to Admitmattshlosberg.substack.com
- New Sciencenewscience.org
- Traversing industry and academia in biomedicine: the best of both worlds? | Nature Reviews Geneticsnature.com
- A primer for academic entrepreneurs on academic-industrial partnerships | Nature Communicationsnature.com
- A primer for academic entrepreneurs on academic-industrial partnerships | Nature Communicationsnature.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz